Kaplan-Meier curves showing the probability of symptom-free survival according to the rate of heart rate rise during exercise testing in (A) for the whole.

Slides:

Advertisements

Similar presentations

Heart valve disease in general practice: a clinical overview by Jessica Webb, Chris Arden, and John B Chambers BJGP Volume 65(632):e204-e206 March 2, 2015.

Advertisements

Pulmonary Hypertension Is Associated with Mortality and Cardiovascular Events in Chronic Kidney Disease Patients Am J Nephrol 2017;45: DOI: /

Survival Benefit of Aortic Valve Replacement in Patients With Severe Aortic Stenosis With Low Ejection Fraction And Low Gradient With Normal Ejection.

Kaplan-Meier survival curves by frequency of exacerbations in patients with COPD: group A, patients with no acute exacerbations of COPD; group B, patients.

Comparison between Kaplan-Meier survival estimates of Bristol aortic valve surgery patients and the Monte Carlo-based generated Kaplan-Meier curve using.

Comparison between Kaplan-Meier survival estimates of Bristol aortic valve surgery patients and the Monte Carlo-based generated Kaplan-Meier curve using.

Baseline characteristics of patients

Kaplan-Meier survival curves comparing survival between both time periods according to management strategy. Survival in patients with infective endocarditis.

Trial profile John A Dormandy et al. Lancet 2005;366:

Aspects to be considered by the Heart Team for the decision between TAVR and SAVR in patients at increased surgical risk. Aspects to be considered by the.

Long-Term Consequences of Postoperative Heart Failure After Surgery for Aortic Stenosis Compared With Coronary Surgery Farkas B. Vánky, MD, PhD, Erik.

MACE rate among CAD severity groups (total 0

Change in symptoms in operated and unoperated patients 1 year following evaluation of surgical AVR. Pie charts display change from baseline to follow-up.

Carotid endarterectomy in patients less than 50 years old

Suggested pathway for assessment of aortic valve replacement dysfunction. Suggested pathway for assessment of aortic valve replacement dysfunction. Transthoracic.

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

Kaplan-Meier curves: revascularisation rate (PCI or CABG) was significantly higher (p

Aortic valve stenosis in community medical practice: Determinants of outcome and implications for aortic valve replacement Joseph Malouf, MD, Thierry.

Management of dilated ascending aorta during aortic valve replacement: Valve replacement alone versus aorta wrapping versus aorta replacement Seung Hyun.

Kaplan-Meier estimate of mortality in 1798 propensity score matched pairs with a propensity score >0.5 for the whole observational period. Kaplan-Meier.

(A) Kaplan-Meier curve showing AF-free survival after a single procedure for patients grouped according to use of CT integration. (A) Kaplan-Meier curve.

Natural History of Ascending Aortic Aneurysms in the Setting of an Unreplaced Bicuspid Aortic Valve Ryan R. Davies, MD, Ryan K. Kaple, BA, Divakar Mandapati,

Aortic Valve Replacement for Patients With Severe Aortic Stenosis: Risk Factors and Their Impact on 30-Month Mortality Edward L. Hannan, PhD, Zaza Samadashvili,

Kevin L. Greason, MD, Brian D. Lahr, MS, John M

Comparison of CMR and echocardiography in aortic regurgitation.

Long-term results estimates for patients with anomalous origin of coronary artery from the pulmonary artery, showing survival, freedom from coronary and.

Cumulative survival without events during 1 year in patients with preserved systolic function (left ventricular ejection fraction (LVEF) >40%) and with.

Associations between β-blocker dosage group, predischarge heart rate group, and the primary composite outcome of death or cardiovascular rehospitalisation.

Kaplan-Meier analysis for the MACE-free or VA-free survival in patients with definite CS (A and C) or suspected CS (B and D) stratified by localisation.

Kaplan-Meier survival curves for the development of diabetes by quartiles of baseline pedometer steps. Kaplan-Meier survival curves for the development.

Kaplan-Meier curves showing the time in months to the first inappropriate shock from the start of remote monitoring in primary and secondary prevention.

Kaplan–Meier survival curve for major adverse cardiac events (MACE): a trend towards superior survival in patients without signs of coronary artery disease.

Distribution of relative percentage change ((post-AVR−pre-AVR)/pre-AVR) in the patients’ absolute pVO2 values between pre-AVR and post-AVR after 9 months.

(A) Mortality in patients with heart failure and different estimated glomerular filtration rate (eGFR) strata, crude survival assessed by Kaplan-Meier.

A large thoracoabdominal aneurysm is being resected.

Multimodality imaging of aortic stenosis.

Perioperative associates of exaggerated heart rate responses pre-exercise. Perioperative associates of exaggerated heart rate responses pre-exercise. (A)

Kaplan-Meier curve of cumulative percentage of cardiac mortality by peak flow rate category (adjusted HRs (95% CI) compared with ≥550 L/min: (

Kaplan–Meyer survival curve of 1313 patients following primary PCI

Kaplan–Meier plots of 5 and 12-year all cause (A and C, respectively) and cardiovascular mortality (B and D, respectively) with number of participants.

Kaplan-Meier survival curves for non-fatal stroke or mortality based on IMRS categories among (A) women (p-trend

Illustration of a trial design to help evaluate the clinical accuracy of a test of ischaemia. Illustration of a trial design to help evaluate the clinical.

Kaplan-Meier survival estimates for major cardiovascular events.

Kaplan-Meier estimation of diabetes-related survival curves in patients grouped according to increased 24-h proteinuria (A), the presence of preexisting.

Kaplan-Meier curves for the end point all-cause mortality in the total patient population stratified according to complete/incomplete revascularisation.

Comparison of survival in patients with BAV (A) and TAV (B) in the US cohort using Kaplan-Meier curves, stratified by whether or not they had suffered.

Cardiac death, target vessel myocardial infarction (MI), target lesion revascularisation (TLR) by Kaplan-Meier method. Cardiac death, target vessel myocardial.

Maxime Berthelot-Richer et al. JIMG 2016;9:

Kaplan-Meier survival curve for CVD mortality among physically active and inactive type 2 diabetic patients stratified by baseline hs-CRP levels. Kaplan-Meier.

Kaplan-Meier survival analysis for all-cause and CVD mortality in 2,823 type 2 diabetic patients stratified by CKD according to each creatinine-based equation.

Kaplan-Meier estimate of mortality in the two treatment strategies with significant difference between the two groups (log-rank test

Survival curves according to the presence of late gadolinium enhancement (LGE) and elevated high-sensitivity C reactive protein (hs-CRP). Survival curves.

Unadjusted event-free survival (days alive and out-of-hospital) of participants with and without MCI in (A) overall cohort, (B) standard management cohort.

Time to first event analysis revealed a significant difference in estimated event-free (death or hospitalisation) survival between patients with left ventricular.

Kaplan-Meier curves for PFS (panel A) and OS (panel B) of patients with mTCC receiving an anti-EGFR based therapy. mTCC, metastatic transverse colon cancer;

Kaplan-Meier survival curves by frequency of exacerbations in patients with COPD: group A, patients with no acute exacerbations of COPD; group B, patients.

Kaplan-Meier survival curves of the IMRS association with non-fatal stroke/mortality (stroke-free survival) in women with AF, stratified by CHA2DS2-VASc.

Time to cessation of rectal bleeding in patients with frank bleeding at baseline. Time to cessation of rectal bleeding in patients with frank bleeding.

Kaplan-Meier estimates of all-cause mortality at 30 days.

A and B, The ROC curves analyzing the sensitivity and specificity of the WHO grading system (I-IV) for the 1-year survival (A) and recurrence (B) show.

Kaplan-Meier plot for the prespecified primary endpoint (CARE-HF (A) and the secondary composite endpoint (all-cause mortality and new onset heart failure.

Independent predictors of all-cause mortality at 30 days.

Mortality rate according to our integrated index that combines DH and exercise capacity. Mortality rate according to our integrated index that combines.

Kaplan-Meier survival (renal event-free) curves during follow-up by tertiles of plasma copeptin. Kaplan-Meier survival (renal event-free) curves during.

Distribution of patient baseline characteristics among included studies. Distribution of patient baseline characteristics among included studies. Each.

(A). (A). Kaplan-Meier plot of event-free survival in 27 LMNA mutation carriers and 78 DCM control patients. Death, heart transplantation, resuscitation.

Kaplan-Meier estimates for survival in metastatic disease for the whole patient cohort (A) and in patients with or without history of adjuvant trastuzumab.

Kaplan-Meier curve of the primary outcome in patients prescribed ACE inhibitor (ACEI) and angiotensin receptor blocker (ARB). Kaplan-Meier curve of the.

(A) Kaplan-Meier estimates of MACCE in patients with a non-culprit MaxLCBI4mm ≥400 and MaxLCBI4mm

Kaplan-Meier survival curves by severity of exacerbations in patients with COPD: (1) no acute exacerbations of COPD; (2) patients with acute exacerbations.

Presentation transcript:

Kaplan-Meier curves showing the probability of symptom-free survival according to the rate of heart rate rise during exercise testing in (A) for the whole study population, and in (B) for the subset of patients who did not develop revealed symptoms on the b... Kaplan-Meier curves showing the probability of symptom-free survival according to the rate of heart rate rise during exercise testing in (A) for the whole study population, and in (B) for the subset of patients who did not develop revealed symptoms on the baseline exercise test and (C) shows event-free survival from all-cause mortality in patients with moderate aortic stenosis and (D) shows event-free survival from aortic valve replacement in patients with severe aortic stenosis. John B Chambers et al. Open Heart 2019;6:e000950 ©2019 by British Cardiovascular Society